Development and initial evaluation of a conversational agent for Alzheimer’s disease

Abstract

Background Conversational Agents have attracted attention for personal and professional use. Their specialisation in the medical field is being explored. Conversational Agents (CA) have accomplished passing-level performance in medical school examinations and shown empathy when responding to patient questions. Alzheimer’s disease is characterized by the progression of cognitive and somatic decline. As the leading cause of dementia in the elderly, it is the subject of continuous investigations, which result in a constant stream of new information. Physicians are expected to keep up with the latest clinical guidelines; however, they aren’t always able to do so due to the large amount of information and their busy schedules.